Janux Therapeutics
JANX
44 hedge funds and large institutions have $353M invested in Janux Therapeutics in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 5 closing their positions.
1.24% more ownership
Funds ownership: 68.21% → 69.45% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 15
6% less funds holding
Funds holding: 47 → 44 (-3)
13% less capital invested
Capital invested by funds: $407M → $353M (-$54.1M)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$3.88M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.76M |
| 3 |
JP Morgan Chase
New York
|
+$1.01M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$990K |
| 5 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
+$586K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$2.5M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$609K |
| 3 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$254K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$185K |
| 5 |
D.E. Shaw & Co
New York
|
-$165K |
JANX Hedge Fund Activity: Q2 2022 in Review
44 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q2 2022, worth a combined $353M — down 13% from $407M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of JANX and 3 opened new positions — a net loss of 2 holders — while 15 trimmed existing stakes and 15 added.
The largest buyer was BVF Inc, adding an estimated $3.88M. The largest seller was Janus Henderson Group, cutting an estimated $2.5M.
- 44 institutional investors held Janux Therapeutics (JANX) as of Q2 2022, down from 47 in Q1 2022.
- Funds reported $353M of Janux Therapeutics stock for Q2 2022, down 13% quarter-over-quarter.
- 3 funds opened new Janux Therapeutics positions in Q2 2022 and 5 closed out, a net change of -2 holders.
- The largest Janux Therapeutics buyer in Q2 2022 was BVF Inc, an estimated $3.88M added.
- The largest Janux Therapeutics seller in Q2 2022 was Janus Henderson Group, an estimated $2.5M sold.
Based on aggregated 13F filings for Q2 2022.